| 104.91 0 (0%) | 03-23 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 122.61 | 1-year : | 143.21 |
| Resists | First : | 104.98 | Second : | 122.61 |
| Pivot price | 103.75  |
|||
| Supports | First : | 103.72 | Second : | 102.94 |
| MAs | MA(5) : | 104.28 |
MA(20) : | 103.65 |
| MA(100) : | 96.55 |
MA(250) : | 69.48 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 94.9 |
D(3) : | 90.2 |
| RSI | RSI(14): 76 | |||
| 52-week | High : | 104.98 | Low : | 38.81 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EXAS ] has closed Bollinger Bands are 78.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 68 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 105.03 - 105.59 | 105.59 - 106.06 |
| Low: | 103.57 - 104.21 | 104.21 - 104.76 |
| Close: | 103.86 - 104.95 | 104.95 - 105.86 |
Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Wed, 03 Jun 2026
Exact Sciences (EXAS): Company Profile, Stock Price, News, Rankings - Fortune
Mon, 23 Mar 2026
Executive equity overhauled as Exact Sciences (EXAS) completes Abbott cash merger - Stock Titan
Mon, 23 Mar 2026
Abbott completes acquisition of Exact Sciences - Yahoo Finance
Mon, 23 Mar 2026
Abbott buys Exact Sciences (NASDAQ: EXAS) in $105-per-share cash merger - Stock Titan
Mon, 23 Mar 2026
Abbott completes $21 billion acquisition of Exact Sciences, delisting EXAS from Nasdaq - Investing.com
Mon, 02 Mar 2026
Exact Sciences Corporation (EXAS) Stock Analysis: Evaluating Growth Prospects Amidst Strong Revenue Growth - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 191 (M) |
| Shares Float | 188 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 86.4 (%) |
| Shares Short | 7,400 (K) |
| Shares Short P.Month | 6,650 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.57 |
| Profit Margin | -6.5 % |
| Operating Margin | -9.3 % |
| Return on Assets (ttm) | -1.6 % |
| Return on Equity (ttm) | -8.7 % |
| Qtrly Rev. Growth | 23.1 % |
| Gross Profit (p.s.) | 11.83 |
| Sales Per Share | 17.02 |
| EBITDA (p.s.) | 0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 491 (M) |
| Levered Free Cash Flow | 282 (M) |
| PE Ratio | -95.38 |
| PEG Ratio | 0 |
| Price to Book value | 8.33 |
| Price to Sales | 6.16 |
| Price to Cash Flow | 40.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|